An Improved Manufacturing Method for Infusible Extracellular Matrix Materials to Enable Efficient Scale-Up, Improved Efficacy, and Clinical Translation
- 1University of California San Diego
Abstract
Decellularized extracellular matrix (ECM) materials are a popular choice for tissue engineering and regenerative medicine applications due to their multifaceted bioactive capabilities arising from their heterogenous composition. For minimally invasive delivery, infusible ECM (iECM) was developed through fractionation of digested decellularized ECM, allowing the material to be safely delivered intravascularly. iECM localizes to permeable vasculature in inflamed tissues and exerts immunomodulatory and pro-reparative effects with proof-of-concept already demonstrated in multiple preclinical models including myocardial infarction (MI) and multiple organ dysfunction syndrome (MODS). However, one major limitation of iECM is the steps required for manufacturing, involving centrifugation, dialysis/lyophilization, and filtration (C-D-F). These steps limit manufacturing output and iECM concentration, and require significant human handling, limiting compliance with current good manufacturing practices (cGMP). To overcome these challenges, we developed a method for manufacturing iECM that utilizes depth filtration and tangential flow filtration (DF-TFF), which reduces manufacturing time, allows for increased iECM concentration, and reduces human manipulation of material, improving translatability and scalability of iECM materials. Based on multiple material characterization methods, we determined that iECM made with DF-TFF was comparable to iECM made with C-D-F. By increasing iECM concentration through this manufacturing method, we demonstrate a dose dependent response in an acute MI porcine model and a mouse MODS model. Finally, DF-TFF enabled timely production of iECM from alternative tissue sources. Altogether, DF-TFF allows for improvements in production time, scale-up, cGMP compliance, and increased dose through higher concentration, paving the way for future clinical translation as well new preclinical studies.
Related
- Design and validation of a GMP-compliant manufacturing platform of extracellular vesicles from mesenchymal stromal cells
- 3D- and 4D-Printed Nano-Enabled Soft Robots for Cancer Diagnosis and Therapy: Materials, Manufacturing, Image Guidance, and Translational Validation.
- Mesenchymal Stem Cell-Derived Extracellular Vesicles for Functional Intracellular Delivery: Engineering, Targeting, Cellular Uptake, Biological Barriers, and Therapeutic Translation
- Harnessing engineered laccase and functional carrier materials for efficient dye degradation: From mechanism to application.
- Biosynthetic additive manufacturing through mycelium-bacteria consortia
BibTeX
@misc{nguyen2026improved,
title = {{An Improved Manufacturing Method for Infusible Extracellular Matrix Materials to Enable Efficient Scale-Up, Improved Efficacy, and Clinical Translation}},
author = {M. Nguyen and E. I. Zelus and M. L. Karkanitsa and B. Liebman and C. Luo and C. Munoz and J. Liu and C. Conklin and P. Cabrales and M. Hepokoski and A. Kinsey and K. L. Christman},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.29.762959},
url = {https://www.biorxiv.org/content/10.64898/2026.10.29.762959v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - An Improved Manufacturing Method for Infusible Extracellular Matrix Materials to Enable Efficient Scale-Up, Improved Efficacy, and Clinical Translation
AU - M. Nguyen
AU - E. I. Zelus
AU - M. L. Karkanitsa
AU - B. Liebman
AU - C. Luo
AU - C. Munoz
AU - J. Liu
AU - C. Conklin
AU - P. Cabrales
AU - M. Hepokoski
AU - A. Kinsey
AU - K. L. Christman
PY - 2026
DA - 2026/10/29
PB - bioRxiv
DO - 10.64898/2026.10.29.762959
UR - https://www.biorxiv.org/content/10.64898/2026.10.29.762959v1
AB - Decellularized extracellular matrix (ECM) materials are a popular choice for tissue engineering and regenerative medicine applications due to their multifaceted bioactive capabilities arising from their heterogenous composition. For minimally invasive delivery, infusible ECM (iECM) was developed through fractionation of digested decellularized ECM, allowing the material to be safely delivered intravascularly. iECM localizes to permeable vasculature in inflamed tissues and exerts immunomodulatory and pro-reparative effects with proof-of-concept already demonstrated in multiple preclinical models including myocardial infarction (MI) and multiple organ dysfunction syndrome (MODS). However, one major limitation of iECM is the steps required for manufacturing, involving centrifugation, dialysis/lyophilization, and filtration (C-D-F). These steps limit manufacturing output and iECM concentration, and require significant human handling, limiting compliance with current good manufacturing practices (cGMP). To overcome these challenges, we developed a method for manufacturing iECM that utilizes depth filtration and tangential flow filtration (DF-TFF), which reduces manufacturing time, allows for increased iECM concentration, and reduces human manipulation of material, improving translatability and scalability of iECM materials. Based on multiple material characterization methods, we determined that iECM made with DF-TFF was comparable to iECM made with C-D-F. By increasing iECM concentration through this manufacturing method, we demonstrate a dose dependent response in an acute MI porcine model and a mouse MODS model. Finally, DF-TFF enabled timely production of iECM from alternative tissue sources. Altogether, DF-TFF allows for improvements in production time, scale-up, cGMP compliance, and increased dose through higher concentration, paving the way for future clinical translation as well new preclinical studies.
ER -